HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anticonvulsant action of a NMDA receptor antagonist CGP 40116 varies only quantitatively during ontogeny in rats.

Abstract
Anticonvulsant action of CGP 40116, a competitive antagonist of N-methyl-D-aspartate type of excitatory amino acid receptors, was studied in rats during development (7, 12, 18, 25 and 90 days old). Two types of motor seizures were elicited by a subcutaneous injection of pentylenetetrazol. Pretreatment with CGP 40116 did not influence minimal, predominantly clonic seizures in any age group. Generalized tonic-clonic seizures were at first modified--their tonic phase was restricted to forelimbs, then selectively suppressed--and with increasing dosage the clonic phase was blocked too. This effect exhibited only minor quantitative changes during development.
AuthorsR Haugvicová, P Mares
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 12 Issue 5 Pg. 521-5 ( 1998) ISSN: 0767-3981 [Print] England
PMID9794150 (Publication Type: Journal Article)
Chemical References
  • Anticonvulsants
  • Receptors, N-Methyl-D-Aspartate
  • 2-amino-4-methyl-5-phosphono-3-pentenoic acid
  • 2-Amino-5-phosphonovalerate
Topics
  • 2-Amino-5-phosphonovalerate (analogs & derivatives, pharmacology)
  • Animals
  • Anticonvulsants (pharmacology)
  • Dose-Response Relationship, Drug
  • Rats
  • Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
  • Seizures (chemically induced, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: